Trial
NCT00994890
A Long Term Study of the Safety of Tanezumab When Administered By Subcutaneous Injections
Phase IITERMINATEDSAFETYConfidence: HIGH
Sponsor
Pfizer
Collaborators
—
Condition
Osteoarthritis, Knee
Intervention
Tanezumab 2.5 mg
Why stopped
See termination reason in detailed description.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-05-13